Trial results

Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial

NCT07734792 on ClinicalTrials.gov · last registry update 2026-07-29

An unusually large phase 2/phase 3: 430 participants, more than double the 60 typical for the stage. Due to report 31 May 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: The primary efficacy outcome: Proportion of patients achieving an excellent functional outcome. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for cardiovascular disease, so this is asking a further question rather than establishing the drug works at all.

Status

NOT_YET_RECRUITING

Phase

P2/P3

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

yifang zhu

Sponsor type

Other

Enrollment

430

Started

2026-08-10

Primary completion

2028-05-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

The primary efficacy outcome: Proportion of patients achieving an excellent functional outcome

Conditions studied

Acute Ischemic Stroke (AIS)

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.